Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-access, Self-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mTc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignancies.

NCT07107633 is registered in ClinicalTrials.gov with Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd. as lead sponsor.

NCT NCT07107633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07107633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-access, Self-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mTc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignancies.
Lead sponsor
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
March 12, 2025
Completion date
September 30, 2025
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peritoneal metastasis, solid tumor